Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients
Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients
This subproject is included in a project coordinated between program groups Evaluation of
 Health Services of Epidemiology and Public Health (Project CAMISS). The overall objective is
 to evaluate different aspects of health care received by patients with breast cancer from the
 diagnostic process, treatment, complications, survival and quality of life, to provide
 information to improve the effectiveness of interventions, reduce variability, have best
 predictive rules and increase the quality of life. The main objective of the subproject is to
 create and validate prospectively predictive rules of recurrence, complications, mortality,
 changes in quality of life in these patients at admission and one/two years of treatment and
 to evaluate the external validity of our rules to predict relapses, complications and
 mortality in the retrospective sample of patients participating in screening programs.
 Observational methodology with information available from a retrospective cohort of women
 diagnosed between 2000 and 2009 and another 2-year prospective follow-up included 2040
 incident cases of breast cancer in 18 hospitals of 5 regions. Cohorts will learn clinical and
 health care diagnosis, tumor, treatment, hospital, follow-up (complications, relapse, and
 vital status) cost and quality of life. Prediction rules are created by means of
 regression/Cox models at the prospective sample and also investigators will assess the
 external validity in the retrospective cohort in the case of recurrence, complications and
 mortality. Expected results: There are currently no results of cohort analysis of the
 diagnostic process of care that integrates different aspects. The study will create tools to
 assist prognostic and therapeutic decision making process in these patients
Inclusion Criteria:

 -  Women over the age of 18 with both incidental in situ and infiltrating breast cancer.

 Exclusion Criteria:

 -  Lymphoma, sarcoma, lobular carcinoma in situ and inflammatory carcinoma of the breast
 are excluded